---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017989"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:19:31.242121+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected

## Summary
- Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).
- All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu; each received majority vote.
- Ratification of Grant Thornton LLP as auditor for fiscal 2025 approved with 4.12M for, 134k against.
- Non-binding advisory vote on executive compensation passed with 2.39M for, 268k against.
- Quorum of 70% (4.33M shares) present at May 21, 2025 annual meeting.

## SEC filing metadata
- accession: 0001437749-25-017989
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925017989/0001437749-25-017989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925017989/aytu20250515_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017989
- JSON: https://secwatch.observer/filing/0001437749-25-017989.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.